GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells

Diabetes/Metabolism Research and Reviews

Volumn 19, Issue 2, 2003, Pages 115-123

  Egan, Josephine M ^a   Bulotta, Angela ^b   Hui, Hongxiang ^b   Perfetti, Riccardo ^b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cells; Diabetes; GLP 1; Insulin secretion; Islets of Langerhans; Pancreatic ductal cells; PDX 1; Stem cells

Indexed keywords

DIFFERENTIATION INDUCING FACTOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GROWTH FACTOR; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LIRAGLUTIDE; PROINSULIN; SOMATOSTATIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL GROWTH; CELL SIZE; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; ENDOCRINE FUNCTION; GENE EXPRESSION; HORMONE ACTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN LIKE ACTIVITY; INSULIN SYNTHESIS; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STOMACH EMPTYING; STRESS;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GROWTH SUBSTANCES; HUMANS; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECEPTORS, GLUCAGON;

EID: 0037357951     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.357     Document Type: Review

References (62)

1. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-333.
2. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329-339.
3. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
4. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetes patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21: 1925-1931.
5. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 2000; 20: 876-913.
6. Drucker DJ. The glucagon-like peptides. Diabetes 1998; 47: 159-169.
7. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-527.
8. Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab 2001; 86: 1759-1764.
9. Wang Y, Perfetti R, Greig NH, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997; 99: 2883-2889.
10. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253-1258.
11. Perfetti R, Zhou J, Doyle ME, Egan JM. GLP-1 induces cell proliferation, PDX-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4600-4605.
12. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein PDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-748.
13. Xu G, Stoffers DA, Habener -F, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
14. Nauck M. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 1996; 13: S39-S43.
15. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322.
16. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (7-37) in normal and diabetic subjects. Regul Pept 1994; 14: 63-74.
17. Dupre J, Behme MT, Hramiak IM, et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 44: 626-630.
18. Perfetti R, Rafizadeh CM, Liotta AS, Egan JM. Age-dependent reduction in insulin secretion and insulin mRNA in isolated islets from rats. Am J Physiol 1995; 269(6 Pt 1): E983-E990.
19. Montanya E, Nacher V, Biarnes M, Soler J. Linear correlation between beta-cell mass and body weight throughout the lifespan in Lewis rats: role of beta-cell hyperplasia and hypertrophy. Diabetes 2000; 49: 1341-1346.
20. Tourrel C, Bailbe D, Meile M-J, Kergoat M, Portha B. Glucagon-like peptide-1 or exendin-4 enhances regeneration of β-cell mass in streptozotocin-treated newborn rats (Abstract). Diabetes 2000; 49(Suppl 1): A257.
21. Aspelund G, Egan JM, Slezak LA, Sritheran KC, Elahi D, Andersen DK. Glucagon-like peptide-1 and exendin-4 improve glucose tolerance and induce islet cell growth in diabetic rats (Abstract). Diabetologia 2000; 43(Suppl 1): A144.
22. Sturis J, Jappe MB, Knudsen LB, et al. The long-acting GLP-1 derivative slows the development of diabetes in the male zucker diabetic fatty rat (Abstract). Diabetes 2000; 49(Suppl 1): A228.
23. Sturis J, Jappe MB, Knudsen LB, et al. The long-acting GLP-1 derivative markedly attenuates diabetes development in the male zucker diabetic fatty rat (Abstract). Diabetologia 2000; (Suppl 1): A145.
24. Liu H, Tuch BE. Effect of glucagon-like peptide 1 and cholecystokinin on fetal β cells (Abstract). Diabetes 1995; 44(Suppl 1): 34A.
25. Nielsen JH, Galsgaard ED, Moldrup A, et al. Regulation of β-cell mass by hormones and growth factors. Diabetes 2000; 50(Suppl 1): S25-S29.
26. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagons-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002; 143: 3152-3161.
27. Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 1999; 140: 778-783.
28. Nie Y, Nakashima M, Brubaker PL, et al. Regulation of pancreatic PC1 and PC2 associated with increased glucagon and GLP-1 immunoreactivity in diabetic rats. J Clin Invest 2000; 105: 955-965.
29. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)cells. Diabetologia 1999; 42: 856-864.
30. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48: 2358-2366.
31. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.
32. Edlund H. Transcribing pancreas. Diabetes 1998; 47: 1817-1823.
33. Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 1993; 12: 4251-4259.
34. Wang RN, Klöppel G, Bouwens L. Duct-to-islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Diabetologia 1995; 38: 1405-1411.
35. Fernandes A, King LC, Guz Y, Stein R, Wright CVE, Teitelman G. Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology 1997; 4: 1750-1762.
36. Wang RN, Bouwens L, Klöppel G. Beta-cell growth in adolescent and adult rats treated with streptozotocin during the neonatal period. Diabetologia 1996; 39: 548-557.
37. O'Reilly LA, Gu D, Sarvetnick N, et al. Alfa cell neogenesis in an animal model of IDDM. Diabetes 1997; 46: 599-606.
38. Anastasi E, Ponte E, Gradini R, et al. Reg and cytokeratin 20 expression during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. Eur J Endocrinol 1999; 141: 644-652.
39. Gu D, Sarvetnick N. Epithelial cell proliferation and islet neogenesis in IFN-g transgenic mice. Development 1993; 118: 33-46.
40. Zulewski H, Abraham EJ, Gerlach MJ, et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 2001; 50: 521-533.
41. de la Tour D, Halvorsen T, Demeterco C, et al. Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 2001; 15: 476-483.
42. Ferber S, Halkin A, Cohen H, et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 2000; 6: 568-572.
43. Drucker DJ, Lovshin J, Baggio L, et al. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Ann N Y Acad Sci 2000; 921: 226-232.
44. Suga S, Kanno T, Ogawa Y, Takeo T, Kamimura N, Wakui M. cAMP-independent decrease of ATP-sensitive K+ channel activity by GLP-1 in rat pancreatic cells. Eur J Physiol 2000; 440: 566-572.
45. Britsch S, Krippeit-Drews P, Lang F, Gregor M, Drews G. Glucagon-like peptide-1 modulates Ca2+ current but not K + ATP current in intact mouse pancreatic B-cells. Biochem Biophys Res Commun 1995; 207: 33-39.
46. Skoglund G, Hussain MA, Holz GG. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 2000; 49: 1156-1164.
47. Hussain MA, Habener JF. Glucagon-like peptide 1 increases glucose-dependent activity of the homeoprotein PDX-1 transactivating domain in pancreatic beta-cells. Biochem Biophys Res Commun 2000; 274: 616-619.
48. Macfarlane WM, Smith SB, James RF, et al. The p38/reactivating kinase mitogen-activated protein kinase cascade mediates the activation of the transcription factor insulin upstream factor 1 and insulin gene transcription by high glucose in pancreatic β-cells. J Biol Chem 1997; 272: 20936-20944.
49. Rodin M, Sekine N, Roche E, et al. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting β-cell line, INS-1. J Biol Chem 1995; 270: 7882-7889.
50. Montrose-Rafizadeh C, Avdonin P, Garant MJ, et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 1999; 140: 1132-1140.
51. Yamauchi J, Nagao M, Kaziro Y, Itch H. Activation of p38 mitogen-activated kinase by signaling through G-protein-coupled receptors. Involvement of Gbetagamma and Ga1phaq/11 subunits. J Biol Chem 1997; 272: 27771-27777.
52. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438.
53. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 1992; 130: 159-166.
54. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995; 136: 4910-4917.
55. Wang X, Cahill C-M, Pineyro MA, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 1999; 140: 4904-4907.
56. Montrose-Rafizadeh C, Egan JM, Roth J. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology 1994; 135: 589-594.
57. Naya FJ, Stellrecht CM, Tsai MJ. Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev 1995; 9: 1009-1019.
58. Susini S, Roche E, Prentki M, Schlegel W. Glucose and glucoincretine peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic β (INS-1) cells. FASEB J 1998; 12: 1173-1182.
59. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258.
60. Scrocchi LA, Marshall BA, Cook S-M, Brubaker PL, Drucker D. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 1998; 47: 632-639.
61. Pederson RA, Satkunarajah M, McIntosh CH, et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 1998; 47: 1046-1052.
62. Yamato E, Noma Y, Tahara Y, et al. Suppression of synthesis and release of glucagon by glucagon-like peptide-I (7-36 amide) without effect on mRNA level in isolated rat islets. Biochem Biophys Res Commun 1990; 167: 431-437.